The role of IgE in nonclassical allergic diseases such as chronic spontaneous urticaria (CSU) [300] and CRSwNP [301] is supported by the clinical efficacy and safety of omalizumab, an anti-IgE monoclonal antibody approved for these diseases. This evidence concerns the gene IGHE and chronic idiopathic urticaria.